BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Business

  BioSpace Movers & Shakers: Pfizer, Black Diamond, Rezolute, Transition Bio and More

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

  June 2, 2022

   · 

  7 min read

   · 

  Alex Keown
• 

  Drug Development

  Numinus CEO: Psychedelic-assisted Psychotherapy Still Driven by Perceptions

  BioSpace spoke with Payton Nyquvest, co-founder and CEO of Numinus about changing perceptions around psychedelic-assisted psychotherapy and the company’s work in this space.

  June 2, 2022

   · 

  6 min read

   · 

  Gail Dutton
• 

  Drug Development

  Atreca Slashes One-Fourth Of Workforce in Reorganization Strategy

  Atreca is reducing its staff count by over 25%, covering current employees and open roles, and revising its operating plan to reflect these cost-cutting measures.

  June 2, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Drug Development

  Money on the Move: Sapience Scores $41m Backed by BMS, NexPoint

  Most money moves happened in Europe this week, including a government-backed award for Parkinson’s disease research and seed funding for an RNA platform.

  June 2, 2022

   · 

  4 min read

   · 

  Hannah Chudleigh
• 

  Business

  Roche, Repare Ink $1.2B Deal for Development of Cancer Therapy

  Repare Therapeutics announced a global cancer collaboration valued at up to $1.2 billion with Swiss pharma giant Roche for the development and commercialization of camonsertib.

  June 2, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Drug Development

  Kids Under 5 Could Soon Be Eligible for Pfizer-BioNTech’s COVID-19 Vaccine

  Children under the age of five could be eligible to receive Pfizer-BioNTech’s vaccine against COVID-19 as soon as late June.

  June 2, 2022

   · 

  2 min read

   · 

  Hayley Shasteen
• 

  Drug Development

  Safety Signal Leads Centessa to Discontinue Development of Lead Asset

  Centessa announced Thursday it is discontinuing the development of its lead asset, lixivaptan, for autosomal dominant polycystic kidney disease (ADPKD).

  June 2, 2022

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  Research Roundup: Gene Regulation and Longevity, Comparing COVID-19 Vaccines

  Top research stories, including gene regulation and longevity, a head-to-head comparison of COVID-19 vaccines, a newly discovered type of brain cell and more.

  June 2, 2022

   · 

  5 min read

   · 

  Mark Terry
• 

  Drug Development

  Outbreak Updates: Monkeypox Highlights Animal-to-Human Interface, Dogs Sniff Out COVID-19

  Monkeypox is not COVID-19, but both are viral diseases that are front-and-center in the world of public health and epidemiology. Here’s a look at the latest news on both outbreaks.

  June 2, 2022

   · 

  4 min read

   · 

  Mark Terry
• 

  Business

  New Month, New Collaborations: BMS, Sorrento & Others Announce New Alliances

  With June just getting started, BMS and Sorrento are making new connections. Read on for announcements of these collaborations.

  June 2, 2022

   · 

  3 min read

   · 

  Hayley Shasteen